SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc.

NEW YORK, May 30, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are encouraged to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether Abeona and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At 22 April 2024Abeona issued a press release “announcing a regulatory update for Prademagene Zamikeracel (pz-cel).” Abeona’s press release states: “The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s Biologics License Application (BLA) for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). The CRL follows the completion of Abeona’s Late Cycle Review Meeting with the FDA in March 2024. At the Late Cycle Review Meeting and in a subsequent request for information, FDA determined that certain additional information needed to meet Chemistry Manufacturing and Controls (CMC) requirements must be satisfactorily resolved before the application can be approved. In response, the Company submitted plans to FDA with a commitment to provide CMC data prior to BLA approval and full post-approval validation reports in mid-2024. In addition, the Company discussed these plans with FDA in a subsequent informal meeting. In the CRL, FDA indicated that Abeona’s proposed timing of data submission would not allow sufficient time for FDA to complete its review by May 25, 2024 PDUFA date.”

Following this news, Abeona’s share price fell 3,95 € per share or 53.67% and closed at $3.41 per share on 23 April 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of victims of securities class action litigation. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.